|
Other Equity and Common Stock Transactions (Details 2) (USD $)
|
0 Months Ended | 3 Months Ended | 9 Months Ended |
|---|---|---|---|
|
Dec. 18, 2012
|
Apr. 30, 2013
|
Apr. 30, 2013
|
|
| Other Equity and Common Stock Transactions | |||
| Authorized issuance of shares to University of South Florida Research Foundation | 150,000 | ||
| Value of shares issued to the University of South Florida Research Foundation | $ 34,500 | ||
| First payment upon the start of future phase II clinical trial | 50,000 | ||
| Payment upon the start of future phase III clinical trial | 100,000 | ||
| Payment upon FDA approval | 250,000 | ||
| Dividends paid | $ 0 | $ 0 |
| X | ||||||||||
|
- Definition
Represents the payment due on FDA approval under the agreement to license certain intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the payment due on start of future phase II clinical trial under the agreement to license certain intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the payment due on start of future phase III clinical trial under the agreement to license certain intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the number of shares authorized to issuance under an agreement to license intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Represents the value of shares authorized for issuance under an agreement to license intellectual property. No definition available.
|
| X | ||||||||||
|
- Definition
Equity impact of aggregate cash, stock, and paid-in-kind dividends declared for common shareholders during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|